The BioMed X Institute
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The project entitled "New Strategies to Engage Neutrophils in Solid Tumors" will be hosted by the BioMed X Institute in Heidelberg, Germany. The goal of this research project is to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.
Developing immunotherapies that target T cells has proved highly effective, and it is still a rapidly evolving research area. However, many patients remain resistant to these therapies, necessitating the development of novel immunological strategies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems to be paradoxical according to the data accumulated thus far. By uncovering novel neutrophil biology, this project aims to leverage their functions to design novel immunotherapies.
The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C03 before February 18, 2024.
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X. We are proud and honored that Ono has chosen our institute to develop new strategies for engaging neutrophils in cancer therapy".
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono Pharmaceutical: "We are very pleased to form a partnership with BioMed X in our mission dedicated to overcoming cancer. This innovative research collaboration will engage us with highly talented scientists around the world who possess unique ideas for immunotherapy utilizing neutrophils. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy with us".
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
About Ono
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
View the original press release on newswire.com.
SOURCE: BioMed X Institute
To view this piece of content from stats.newswire.com, please give your consent at the top of this page. To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Investment Firm Alpha Star invests 1 million USD in AI Art Authentication Company Art Recognition29.10.2025 11:00:00 CET | Press release
ZURICH, SWITZERLAND / ACCESS Newswire / October 29, 2025 / Art Recognition , the Swiss pioneer in AI art authentication, is delighted to announce a new strategic partnership with Alpha Star , a leading Luxembourg-based investment fund with a strong track record of supporting innovative companies in the art market. This collaboration marks an important milestone as Alpha Star becomes Art Recognition's anchor investor. The partnership will accelerate Art Recognition's growth and strengthen its position as a trusted technology partner for the art world, helping bring greater transparency, confidence, and innovation to art authentication. "We are thrilled to welcome Alpha Star as a key partner on our journey," said Carina Popovici, CEO and Founder of Art Recognition. "Their confidence in our technology and vision is a strong endorsement of the role AI will play in shaping the future of the art world." "We are excited to support Art Recognition in its mission to bring cutting-edge AI techno
Ecological Threat Report 2025: Extreme Wet-Dry Seasons Emerge as Critical Conflict Catalyst29.10.2025 06:00:00 CET | Press release
Approximately 2 billion people - one quarter of humanity - now live in regions experiencing moderate to severe increases in seasonality LONDON, GB / ACCESS Newswire / October 29, 2025 / New research from the Institute for Economics & Peace reveals that changing rainfall patterns are significantly amplifying conflict risks worldwide. The 2025 Ecological Threat Report (ETR), released today, finds conflict death rates are substantially higher in areas where rainfall is concentrating into fewer months, compared to regions where rain is spreading more evenly throughout the year.Ecological Threat Report 2025 Analysing Ecological Threats, Resilience & Peace Key Findings On average in areas where wet and dry seasons are becoming more extreme, there are four times as many conflict deaths as areas where it has decreased. In 2024, natural hazards triggered 45 million short-term internal displacements across 163 countries, the highest figure since at least 2008. Western Brazil, including parts of
Karbon-X Celebrates Major Milestone in Senegal Mangrove Restoration Project28.10.2025 13:00:00 CET | Press release
Planting completed across 7,000 hectares in partnership with Woodside Energy, advancing community-led climate action. DAKAR, SN / ACCESS Newswire / October 28, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to announce a significant milestone in its ABC Mangrove Project, one of West Africa's largest community-led restoration initiatives with the successful completion of planting across more than 7,000 hectares of mangroves along Senegal's coastline. Developed through ALLCOT, Karbon-X's project development and advisory arm (ALLCOT-A Karbon-X Company), and in partnership with Woodside Energy, the project is helping restore critical blue-carbon ecosystems that protect biodiversity, strengthen local economies, and capture carbon naturally from the atmosphere. Through this multi-year effort, thousands of local community members have been engaged in the planting and care of mangroves, creating new jobs, skills training, and sustainable income opportunities for wome
Florence Healthcare Launches SiteLink on AWS Marketplace, Extending its Clinical Trial Operations Platform Capabilities to Cloud28.10.2025 13:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / October 28, 2025 / Florence Healthcare, the leading clinical trial platform connecting pharmaceutical sponsors and research sites worldwide, announced today that SiteLink, a key offering of Florence's Trial Operations Platform, is now available in AWS Marketplace. SiteLink accelerates study startup and enables real-time document distribution, monitoring, and data exchange with study sites, addressing the critical digital divide in clinical trials. With only 30% of global research sites currently using digital workflows, SiteLink helps bridge this gap by automating sponsor-site operational workflows. Bringing the Florence Trial Operations Platform Benefits to AWS As a core component of Florence's Trial Operations Platform, SiteLink delivers the same proven results that have made Florence the #1 clinical trial management solution for six consecutive years. The platform enables: Faster Startup: Up to 70% faster study activation timelines through automa
GoodData Brings AI-Native Data Intelligence to Financial Services28.10.2025 10:00:00 CET | Press release
Embeddable, compliant, and auditable AI agents unlock trusted automation for banks, insurers, and financial institutions. SAN FRANCISCO, CA / ACCESS Newswire / October 28, 2025 / GoodData, a leading analytics and data intelligence company, today unveiled new finance-focused applications for its composable AI platform, designed to tackle the industry's toughest challenges. By combining its AI Lake, AI Hub, and AI Apps into a single foundation for enterprise data intelligence, the next-generation platform gives financial institutions powerful tools to build and deploy AI agents. These agents can detect and investigate fraud in seconds with audit trails regulators can trust, keeping portfolios compliant in real time within industry guidelines. This streamlines regulatory reporting by compiling, checking, and submitting disclosures transparently, all while meeting strict standards for financial compliance, governance, and security. Purpose-built for finance The financial services sector fa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom